Evidence map›Paper›PMID 35522322›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2022

Classification of

Mariska Reinartz, Emma Susanne Luckett, Jolien Schaeverbeke, Steffi De Meyer, Katarzyna Adamczuk, Dietmar Rudolf Thal, Koen Van Laere, Patrick Dupont, Rik Vandenberghe

Open access · hybridAbstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Support vector machine classification ofEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Review
  4. Centiloid recommendations for clinical context-of-use from the AMYPAD consortium.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Mariska ReinartzLaboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.ORCID 0000-0001-7964-7963
Emma Susanne LuckettLaboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.ORCID 0000-0003-1777-4742
Jolien SchaeverbekeLaboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.
Steffi De MeyerLaboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.
Katarzyna AdamczukBioclinica, Newark, CA, 94560, USA.
Dietmar Rudolf ThalDepartment of Pathology, UZ Leuven, Leuven, Belgium.
Koen Van LaereDivision of Nuclear Medicine, UZ Leuven, Leuven, Belgium.
Patrick DupontLaboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.ORCID 0000-0003-1980-2540
Rik VandenbergheLaboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium. rik.vandenberghe@uzleuven.be.ORCID 0000-0001-6237-2502
VIB-KU Leuven Center for Brain & Disease Research · BEUniversitair Ziekenhuis Leuven · BEAllen Institute for Brain Science · USBioClinica (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEnd-of-life studies have validated the binary visual reads of

methodsWe applied SVM with a linear kernel to an

resultsThe classifiers yielded adequate specificity and sensitivity within the end-of-life dataset (neuritic amyloid plaque density classifier: specificity of 90.2% and sensitivity of 83.7%; amyloid phase classifier: specificity of 98.4% and sensitivity of 84.0%). The regions with the highest feature weights corresponded to precuneus, caudate, anteromedial prefrontal, and also posterior inferior temporal and inferior parietal cortex. In the cognitively normal cohort, the correlation coefficient between CL and distance to the hyperplane was -0.66 for the classifier trained with neuritic amyloid plaque density, and -0.88 for the classifier trained with amyloid phases. This difference was significant. The optimal CL cut-off for discriminating positive versus negative scans was CL = 48-51 for the different classifiers (area under the curve (AUC) = 99.9%), except for the classifier trained with amyloid phases and based on the 10% voxels with highest feature weights. There the cut-off was CL = 26 (AUC = 99.5%), which closely matched the CL threshold for discriminating phases 0-2 from 3-5 based on the end-of-life dataset and the neuropathological ground truth. DISCUSSION: Among a set of neuropathologically validated classifiers trained with end-of-life cases, transfer to a cognitively normal population works best for a classifier trained with amyloid phases and using only voxels with the highest amplitudes of feature weights.

Indexed as

Alzheimer DiseasePlaque, AmyloidAgedAmyloidAniline CompoundsBenzothiazolesDeathHumansMachine LearningPositron-Emission TomographyAmyloidAniline CompoundsBenzothiazolesflutemetamol18F-FlutemetamolAlzheimer’s disease (AD)ClassificationNeuropathologyPositron emission tomography (PET)Support vector machine (SVM)

Identifiers

PMID35522322
PMCPMC9399207
OpenAlexW4229008018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.